Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis

2022-502997-18-00 Protocol IM034-1014 Human pharmacology (Phase I) - Other Ended

Start 2 Feb 2024 · End 6 Nov 2025 · Status Ended · 5 EU/EEA countries · 17 sites · Protocol IM034-1014

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 64
Countries 5
Sites 17

Atopic Dermatitis

Key facts

Sponsor
Bristol-Myers Squibb Services Unlimited Company
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trial duration
2 Feb 2024 → 6 Nov 2025
Decision date (initial)
2023-09-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-502997-18-00
WHO UTN
U1111-1283-0050

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Atopic Dermatitis

VersionLevelCodeTermSystem organ class
21.1 LLT 10003639 Atopic dermatitis 10040785

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bristol-Myers Squibb Services Unlimited Company

Sponsor organisation
Bristol-Myers Squibb Services Unlimited Company
Address
Plaza 254 Blanchardstown Corporate Park 2, Ballycoolin Ballycoolin
City
Dublin 15
Postcode
D15 T867
Country
Ireland

Scientific contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Public contact point

Organisation
Bristol-Myers Squibb Services Unlimited Company
Contact name
GSM-CT

Locations

5 EU/EEA countries · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ended 6 2
France Ended 30 3
Germany Ended 6 6
Poland Ended 10 4
Spain Ended 12 2
Rest of world 0

Investigational sites

Czechia

2 sites · Ended
Clintrial s.r.o.
Dermatology, Pocernicka 1427/16, Strasnice, Prague 10
Pratia Pardubice a.s.
Dermatology, Trida Miru 2800, Zelene Predmesti, Pardubice I

France

3 sites · Ended
Hospices Civils De Lyon
Allergy and Clinical Immunology Department, 165 Chemin Du Grand Revoyet, 69310, Pierre-Benite
University Hospital Of Clermont-Ferrand
Department of Dermatology, 1 Place Lucie Et Raymond Aubrac, 63100, Clermont-Ferrand
Centre Hospitalier Universitaire De Nice
Department of Dermatology, 151 Route De Saint Antoine, 06200, Nice

Germany

6 sites · Ended
Staedtisches Klinikum Dessau
Department of dermatology, Venerology, Allergology and Immunology, Auenweg 38, Alten, Dessau-Rosslau
Charite Research Organisation GmbH
Medical Operations, Chariteplatz 1, Mitte, Berlin
Universitaetsklinikum Heidelberg AöR
Dermatology, Im Neuenheimer Feld 440, Neuenheim, Heidelberg
University Medical Centre Schleswig-Holstein
Comprehensive Center for Inflammation Medicine, Ratzeburger Allee 160, 23538, Lübeck
Deutsches Rotes Kreuz Gemeinnuetzige Krankenhaus GmbH Sachsen
Dermatology, Unritzstrasse 23, Rabenstein, Chemnitz
Gesundheit Nord gGmbH Klinikverbund Bremen
Department of Dermatology, Zuericher Strasse 40, Ellenerbrok-Schevemoor, Bremen

Poland

4 sites · Ended
Wromedica I Bielicka A Strzalkowska s.c.
Dermatology, Ul. Adama Mickiewicza 91, 51-685, Wroclaw
Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie
Klinika Dermatologii, Ul. Fryderyka Szopena 2, 35-055, Rzeszow
Pratia S.A.
NA, Ul. Dabrowki 13, 40-081, Katowice
Malopolskie Centrum Kliniczne
NA, Ul. Balicka 12a/5b, 30-149, Cracow

Spain

2 sites · Ended
Hospital Universitario De Gran Canaria Dr. Negrin
Dermatology, Barranco De La Ballena Sn, 35010, Las Palmas De Gran Canaria
Hospital Universitario Reina Sofia
Dermatology, Avenida Menendez Pidal S/n, 14004, Cordoba

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2024-06-12 2025-11-06 2024-07-17 2025-03-25
France 2024-03-20 2025-01-16 2024-05-14 2024-06-06
Germany 2024-03-08 2025-08-26 2024-03-28 2024-11-04
Poland 2024-02-28 2025-11-04 2024-03-06 2025-03-19
Spain 2024-02-02 2024-10-30 2024-06-19 2024-07-03

Application history

16 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-18 Germany Acceptable
2023-09-11
2023-09-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-09-22 Germany Acceptable
2023-09-11
2023-09-22
3 SUBSTANTIAL MODIFICATION SM-1 2023-09-29 Acceptable 2023-12-14
4 SUBSTANTIAL MODIFICATION SM-3 2023-09-29 Germany Acceptable 2023-10-23
5 SUBSTANTIAL MODIFICATION SM-4 2023-09-29 Acceptable 2023-10-28
6 SUBSTANTIAL MODIFICATION SM-5 2023-09-29 Acceptable 2023-11-29
7 SUBSTANTIAL MODIFICATION SM-2 2023-10-06 Acceptable 2023-11-15
8 NON SUBSTANTIAL MODIFICATION NSM-2 2024-01-12 Germany Acceptable 2024-01-12
9 SUBSTANTIAL MODIFICATION SM-6 2024-01-15 Acceptable 2024-02-06
10 NON SUBSTANTIAL MODIFICATION NSM-3 2024-02-20 Germany Acceptable 2024-02-20
11 NON SUBSTANTIAL MODIFICATION NSM-4 2024-04-01 Germany Acceptable 2024-04-01
12 SUBSTANTIAL MODIFICATION SM-7 2024-04-05 Germany Acceptable 2024-04-29
13 SUBSTANTIAL MODIFICATION SM-8 2024-05-28 Acceptable 2024-07-15
14 SUBSTANTIAL MODIFICATION SM-9 2024-09-12 Germany Acceptable 2024-11-08
15 SUBSTANTIAL MODIFICATION SM-10 2024-11-19 Acceptable 2025-01-10
16 NON SUBSTANTIAL MODIFICATION NSM-5 2025-11-05 Germany Acceptable 2025-11-05